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Abstract  
 
Normal individuals have mature T lymphocytes that are capable of reacting to self-
antigens and can be activated by cross-reacting environmental antigens. The 
mechanism that maintains immune tolerance and pre-vents these activated autoreactive 
T cells from causing autoimmune disease is unclear. We have previously hypothesized 
that activation-induced apoptosis of previously activated autoreactive T cells in the 
target organ is a major mechanism for maintaining tolerance. Here I review the current 
evidence to support this hypothesis. It is proposed that when activated autoreactive T 
cells enter the target organ, they are reactivated mainly by non-professional antigen-
presenting cells (APC) and deleted by activation-induced apoptosis through the Fas 
(CD95) pathway before producing significant target organ damage. This apoptosis 
occurs because the reactivated T cells do not receive sufficient costimulation from the 
non-professional APC to up-regulate their expression of Bcl-2-related anti-apoptotic 
proteins, which inhibit the CD95 pro-apoptotic pathway. This is in contrast to the 
situation in peripheral lymphoid organs, where reactivation of T cells by professional 
APC results in sufficient costimulation-induced up-regulation of Bcl-2-related 
proteins to inhibit the CD95 pathway and allow T cell proliferation and survival as 
memory T cells. Activation-induced apoptosis of alloreactive T cells in allografts can 
similarly account for spontaneous allograft acceptance, as occurs after MHC-
mismatched liver transplantation. 
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Introduction  
 
Tolerance 
 
All normal individuals have T lymphocytes capable of reacting to self-antigens. Because there is 
increasing evidence that T cells are much more cross-reactive than previously thought,1 it is likely 
that these autoreactive T cells are often primed by exposure to cross-reacting environmental 
antigens. Why then do normal individuals not develop autoimmune disease? The question of the 
mechanism of immune tolerance is an old one, but the evidence that T cells are highly cross-
reactive emphasizes the importance of immune tolerance in allowing normal function and survival 
of the body and its organs. Some definitions of immune tolerance make assumptions about the 
mechanism of tolerance and lead to confusion. In the present article, tolerance will be defined as 
the survival of the normal structure and function of a tissue or organ in the presence of an 
activated immune response against components of the tissue or organ. Immune tolerance applies not 
only to self-tolerance, but also to the spontaneous tolerance that develops after organ 
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transplantation, particularly of the liver. Explanations for immune tolerance that depend on 
sequestration of tissue-specific antigens are inadequate to account for immune tolerance, in view 
of the high level of T cell cross-reactivity. Autoreactive T cells activated by cross-reacting 
environmental antigens will enter any organ, including those with blood–tissue barriers such as the 
brain,2,3 and will eventually encounter their target antigen. 
A number of mechanisms have been proposed to maintain immune tolerance through the 
regulation of activated T cells. These include T cell anergy, regulatory T cells producing 
immunosuppressive cytokines and activation-induced T cell apoptosis in undefined sites.4 The 
present article will review the current evidence supporting our previously proposed hypothesis that 
activation-induced T cell apoptosis in the target organ is a major mechanism of immune 
tolerance.5,6 
 
Activation-induced T cell apoptosis 
 
The term ‘activation-induced apoptosis’ refers to the apoptosis of thymocytes or previously 
activated mature T cells, triggered by activation through the T cell receptor (TCR).7,8 Activation-
induced apoptosis of mature T cells is mediated through the activation of the Fas (CD95) pathway 
and related death receptor pathways.9–13 The CD95 pathway is activated by the ligation of cell 
surface CD95 by CD95 ligand (CD95L; also known as Fas ligand) and can occur by the 
interaction of CD95 and CD95L on the same T cell.10,11 T cell receptor ligation up-regulates CD95 
expression10,12 and induces the expression of CD95L.9,10,12 The intracellular signalling pathway for 
CD95 and related death receptors is dependent on the activity of a number of cysteine proteases 
(caspases).13 Ligation of CD95 by the homotrimeric CD95L results in the clustering of CD95 and 
the recruitment of the adaptor protein Fas-associated death domain (FADD) to the clustered CD95 
intracellular death domains. Caspase-8, an upstream caspase which binds to FADD, is then 
activated by self-cleavage as a result of induced oligomerization. 
Activated caspase-8 can mediate apoptosis via two pathways: (i) direct activation of 
downstream effector caspases (such as caspase-3) by direct cleavage; or (ii) indirect activation of 
downstream effector caspases by causing the release of cytochrome c from mitochondria.14 Bcl-2 
and Bcl-xL block downstream caspase activation and apoptosis mediated by the indirect CD95 
signalling pathway, but not by the direct pathway.14 The contributions of these two pathways vary 
among different cell types, probably owing to different levels of activated caspase-8 and its 
downstream substrates. It appears that some T cells use the direct pathway14,15 whereas other T 
cells use the indirect pathway.14 In the direct pathway, a large amount of caspase-8 is activated 
following CD95 cross-linking and this directly cleaves and thereby activates downstream caspases 
such as caspase-3, which mediate the final destruction of the cell including DNA cleavage and the 
morphological changes of apoptosis. In the indirect pathway, a small amount of activated caspase-8 
cleaves Bid, a Bcl-2-interacting protein, into a truncated form that promotes cytochrome c 
release from mitochondria, with the resultant activation of the downstream effector caspases such 
as caspase-3.16,17 It is also possible that truncated Bid may activate downstream caspases by a 
cytochrome c-independent pathway.16 Bid contains the Bcl-2 homologous domain 3 (BH3 
domain), through which it interacts with Bcl-2-related proteins that can inhibit the apoptotic 
changes induced by truncated Bid. The interaction of Bid with Bcl-2-related proteins can explain 
the inhibition of CD95-mediated apoptosis by Bcl-214,18,19 and Bcl-xL.14,20 
There is evidence that costimulation of previously activated T cells influences their survival. 
Costimulation by professional APC21,22 or by the direct ligation of CD2823 inhibits activation-
induced apoptosis of previously activated T cells. Interleukin (IL)-2, expression of which is 
increased by co-stimulation of previously activated T cells,24 increases the expression of Bcl-225,26 
and inhibits activation-induced apoptosis of previously activated T cells.22,27 Furthermore, CD28 
costimulation enhances the expression of Bcl-x,20,26 which can inhibit activation-induced T cell 
apoptosis.20 The inhibitory effect of Bcl-2-related proteins on activation-induced T cell death may 
be accounted for by their interaction with Bid and their inhibition of the CD95 pathway (see 
earlier). CD28 costimulation may also prevent the induction of CD95L expression.23 Therefore, 
whether TCR reactivation results in T cell death or survival depends on the balance between pro-
apoptotic and anti-apoptotic factors. Repeated TCR activation promotes the CD95 pro-apoptotic 
pathway, whereas costimulation promotes the Bcl-2-related anti-apoptotic pathway. It is probable 
that effector T cells are like other previously activated T cells in their dependence on costimulation 
for survival. Thus, the reactivation of effector T cells in the absence of costimulation may lead to 
final effector function and cell death, whereas the reactivation of effector T cells in the presence 
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of costimulation may allow ongoing effector function and eventual persistence as memory T cells. 
This would be consistent with the linear differentiation pathway model of memory T cell 
differentiation, in which memory T cells are derived directly from effector cells.28 Effector T cells 
may differ from other previously activated T cells only by having a shorter time interval since last 
being activated. 
The inhibitory action of IL-2 on activation-induced T cell apoptosis22,27 appears to contradict 
the observation that previous exposure to IL-2 increases the susceptibility to activation-induced 
apoptosis.29 This discrepancy can be explained by differences in the timing of IL-2 exposure. The 
increased susceptibility to activation-induced cell death of T cells previously exposed to IL-2 may 
be due to the IL-2-induced up-regulation of CD95L expression and suppression of the expression 
of FLICE (caspase-8)-inhibitory protein (FLIP), an inhibitor of CD95 signalling.30 Thus, previous 
activation through the TCR and IL-2 increases the susceptibility to activation-induced apoptosis, 
which can be overcome by further IL-2 at the time of reactivation of the TCR. The outcome of 
TCR reactivation is determined by the balance between proapoptotic and anti-apoptotic factors, 
which are influenced by the circumstances of previous and present T cell activation. 
The site of activation-induced apoptosis of previously activated T cells also needs to be 
considered. For autoreactive and all reactive T cells, the target organ is likely to be the site of 
activation-induced apoptosis for two reasons. First, the target organ contains the greatest amount 
of antigen recognized by the T cells. Second, it also contains non-professional APC, which can 
present this antigen to the TCR in the context of class I or class II major histocompatibility 
complex (MHC) molecules, but which fail to provide sufficient costimulation to inhibit activation-
induced apoptosis. We have previously hypothesized that activation-induced apoptosis of 
autoreactive T cells in the target organ following reactivation by non-professional APC is a general 
mechanism for maintaining T cell tolerance and protecting against autoimmune disease.5,6 A 
model for T cell tolerance depending on the lack of costimulation in the target organ has also been 
proposed by Matzinger.31 T cell apoptosis will now be considered in the various target organs in 
which it has so far been reported or implicated. 
 
T cell apoptosis in the central nervous system  
 
Experimental autoimmune encephalomyelitis 
 
Experimental autoimmune encephalomyelitis (EAE) is a T cell-mediated autoimmune 
demyelinating disease of the central nervous system (CNS) that is widely studied as a model of the 
human demyelinating disease multiple sclerosis.32 T cell apoptosis occurs in the CNS in rats with 
acute EAE and has been proposed to contribute to the spontaneous recovery from acute EAE and 
the development of tolerance.5,33,34 It is maximal at the time of spontaneous clinical recovery34–36 
and is a major mechanism for eliminating encephalitogenic T cells from the CNS.35–38 This T cell 
apoptosis is consistent with the relative lack of T cell proliferation in the CNS in acute EAE.39 It 
should be noted that macrophages,40–42 microglia41,42 and B cells (CA White et al., unpubl. obs., 
1999) also undergo apoptosis in the CNS in EAE. To study T cell apoptosis in the target organ, it is 
therefore essential to demonstrate apoptosis of cells expressing T cell markers rather than simply 
demonstrating apoptosis in an unlabelled inflammatory cell infiltrate. 
It has been proposed that the apoptotic deletion of auto-reactive T cells in the CNS is due to 
activation-induced apoptosis following reactivation by CNS non-professional APC, such as 
astrocytes or microglia, which fail to deliver the co-stimulatory signal needed to inhibit activation-
induced apoptosis.5,35,37 This is supported by studies showing that the T cell apoptotic process in the 
CNS selectively affects CNS-reactive T cells, whereas the activated non-CNS-reactive T cells that 
accumulate in the CNS in EAE recirculate to the peripheral lymphoid organs.35,37 It is also 
supported by the following additional in vivo observations. First, the apoptosis of auto-reactive T 
cells in the CNS in EAE is inhibited by the administration of glucocorticoid,43 which is known to 
antagonize activation-induced apoptosis in vitro, probably at least in part by reducing the 
expression of CD95L.44,45 Second, autoreactive T cells expressing CD95 or CD95L are highly 
vulnerable to apoptosis in the CNS in EAE, whereas autoreactive T cells expressing Bcl-2 are 
relatively protected from apoptosis.46 Third, the intraperitoneal administration of the soluble target 
antigen, myelin basic protein, markedly increases the level of CD95-dependent autoreactive T cell 
apoptosis in the CNS, but not in the peripheral lymphoid organs, and ameliorates the disease in 
rats with EAE.47 Given that the systemic administration of soluble myelin basic protein should 
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result in its distribution throughout lymphoid and non-lymphoid organs including the CNS, this 
finding indicates that the environment in the CNS is more conducive to activation-induced T cell 
apoptosis than the environment of the spleen or the lymph node draining the site of inoculation 
with myelin basic protein and adjuvants. One possible explanation is that professional APC in the 
peripheral lymphoid organs provide high levels of costimulation with resultant high T cell levels of 
anti-apoptotic proteins, such as Bcl-2, which inhibit CD95-mediated activation-induced apoptosis, 
whereas the predominantly non-professional APC in the CNS are unable to provide sufficient 
costimulation to inhibit this apoptosis. Autoreactive T cells in the CNS may also have higher 
levels of CD95 and CD95L expression than those in the peripheral lymphoid organs, because they 
are more likely to have been repeatedly activated by antigen. 
In vitro studies have implicated astrocytes and microglia as CNS non-professional APC that 
induce T cell apoptosis by their interactions with autoreactive T cells. Antigen presentation by 
astrocytes inhibits T cell proliferation48 and primes T cells for apoptosis.49 Antigen presentation to 
autoreactive CD4+ T cells by microglia results in T cell apoptosis which can be prevented by the 
addition of IL-2.27 The finding that apoptotic cells are more closely associated with astrocytes than 
with microglia in the CNS in EAE has been interpreted as indicating that astrocytes, rather than 
microglia, induce T cell apoptosis.50 However, the fact that microglia express considerably higher 
levels of class II MHC molecules than astrocytes in EAE and that this increases during the clinical 
course51 indicates that microglia are more likely than astrocytes to present antigen to T cells in 
vivo. 
The conclusion that the T cell apoptotic process in the CNS in EAE selectively affects CNS-
reactive T cells35–37 has recently been challenged by the finding that non-CNS-reactive T cells also 
undergo apoptosis in the CNS in acute EAE.38 However, the level of non-CNS-reactive T cell 
apoptosis appeared to be considerably less than the level of CNS-reactive T cell apoptosis and may 
be explained by the effects of the endogenous release of corticosterone, which occurs during 
spontaneous clinical recovery from moderate to severe EAE,52 but not from mild EAE.53 This is 
supported by the fact that adrenalectomy reduces T cell apoptosis in the CNS in EAE53 and that 
the administration of the glucocorticoid dexamethasone increases apoptosis of non-CNS-reactive, 
but not CNS-reactive, T cells.41,43 Thus, the T cell apoptosis in the CNS in EAE may be due to a 
combination of activation-induced apoptosis of CNS-reactive T cells and glucocorticoid-induced 
apoptosis of non-CNS-reactive T cells. The occurrence of T cell apoptosis in the CNS of bone 
marrow chimeras with EAE induced by the passive transfer of encephalitogenic T cells with a 
different MHC than the resident CNS cells has been interpreted as indicating that T cell apoptosis 
is not dependent on antigen presentation by CNS parenchymal glial cells.38 However, the TCR of 
the encephalitogenic T cells may still interact with the MHC–peptide complex of the CNS 
parenchymal cells in an alloreactive response because of the MHC mismatch and the 
encephalitogenic T cells may be deleted in the same way as T cells are deleted by apoptosis in liver 
transplants54 (see later). Bauer et al. have suggested that CNS-infiltrating T cells of any specificity 
are eliminated by apoptosis through an as yet undetermined mechanism.38 This concept has major 
implications for the maintenance of T cell memory for any antigen, as activated T cells (including 
memory cells) of any specificity can enter the normal or inflamed CNS and would be deleted 
there. This would lead to a progressive loss of memory T cells, particularly if the same process 
also occurred in other organs such as the testis and eye (see later). Such a non-specific deletion of 
all activated T cells would seem to be a poorly controlled waste of useful T cells that would not be 
favourable for the long-term survival of the whole animal. 
The earlier discussion has dealt with spontaneous recovery from acute EAE. Lewis rats that 
have recovered from acute EAE induced by immunization with myelin basic protein and adjuvants 
develop tolerance to myelin basic protein, as evidenced by the resistance to re-induction of EAE 
by active immunization.55 It has been suggested that ongoing activation-induced T cell apoptosis 
in the CNS may contribute to this tolerant state.5 The proportions of auto-reactive T cells 
expressing CD95 and CD95L in the CNS increase during the late recovery phase of EAE, raising 
the possibility that activation-induced apoptosis is enhanced in the previously inflamed CNS 
compared to the normal CNS because of the increased availability of myelin antigens following 
demyelination and the increased class II MHC expression by microglia.46 Increased activation-
induced apoptosis of T cells in previously inflamed regions of the CNS may account for the 
redistribution of lesions in subsequent milder or subclinical episodes of EAE induced by 
rechallenge, a phenomenon termed target organ resistance.56,57 Further studies are needed to 
determine to what extent activation-induced T cell apoptosis contributes to the tolerant state that 
develops after recovery from acute EAE.  
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Multiple sclerosis 
 
Multiple sclerosis is a chronic inflammatory demyelinating disease of the CNS that results in 
recurrent attacks, or some-times a progressive course, of neurological dysfunction. There is 
increasing evidence that multiple sclerosis is an autoimmune disease.58,59 Apoptotic T cells have 
been found in the CNS of patients with multiple sclerosis,60,61 but these may have been non-CNS-
reactive T cells dying by glucocorticoid-induced apoptosis. One study found that T cell apoptosis 
was strikingly infrequent.61 In these studies, apoptosis has been investigated by the detection of 
DNA fragments in situ using the terminal deoxyribonucleotidyl transferase-mediated dUTP-
digoxigenin nick end-labelling (TUNEL) assay. This technique does not discriminate among 
apoptosis, necrosis and postmortem autolysis.62,63 The problem can be overcome if it has already 
been determined by electron microscopy of well fixed tissue that cell death is occurring by 
apoptosis rather than by necrosis. However, it remains a potential problem for suboptimally fixed 
human tissue obtained post-mortem, where autolysis may lead to false-positive results for 
apoptosis. 
It has been hypothesized that multiple sclerosis is due to a genetically determined failure of 
activation-induced apoptosis of autoreactive T cells in the CNS.64 Activation-induced T cell 
apoptosis may fail in the CNS because of two broad types of abnormality. First, there may be an 
abnormality in CNS APC with increased costimulatory ability or possibly decreased CD95L 
expression by these APC. Second, there may be an abnormality in the T cells leading to 
underactivity of the pro-apoptotic CD95 pathway or overactivity of the anti-apoptotic Bcl-2-
related protein family. Further studies are needed to determine whether there is a failure of T cell 
apoptosis in the CNS in multiple sclerosis. 
 
T cell apoptosis in the peripheral nervous system 
 
Experimental autoimmune neuritis is a T cell-mediated auto-immune demyelinating disease of the 
peripheral nervous system. T cell apoptosis occurs in the peripheral nervous system of rats with 
acute experimental autoimmune neuritis.65,66 It is maximal at the time of spontaneous clinical 
recovery and has been suggested to contribute to the recovery process and monophasic clinical 
course. The intravenous administration of the target antigen, P2 protein, markedly increases the 
level of T cell apoptosis in the peripheral nervous system and ameliorates the disease, indicating 
that the apoptosis is due to activation-induced cell death of autoreactive T cells.67 The 
administration of glucocorticoid also increases the level of T cell apoptosis in the peripheral 
nervous system in experimental autoimmune neuritis68 but it has not been determined whether this 
involves the autoreactive or non-autoreactive T cells. 
 
T cell apoptosis in the liver  
 
Autoreactive T cells 
 
Apoptotic inflammatory cells are present in the liver of irradiated transgenic mice that express H-
2Kb in the liver and have been injected with lymph node cells from transgenic mice expressing in 
their T cells a Kb-specific TCR.69 It has been suggested that these apoptotic cells are autoreactive 
(Kb-specific) CD8+ T cells that have been deleted in the liver.69 It has also been proposed that 
naive autoreactive CD8+ T cells circulate to the liver and undergo apoptosis after being activated 
by hepatocytes which act as non-professional APC.70 However, an alternative explanation is that 
the Kb transgene is processed in the draining lymph nodes (as can occur with other self-
antigens71), where it activates the Kb-specific T cells in the context of the background class I MHC 
(H-2k) molecules and the activated Kb-specific T cells then enter the liver, where they are 
reactivated and deleted after interacting with hepatocytes or other non-professional APC 
presenting Kb in the context of the background H-2k molecules. 
 
Alloreactive T cells 
Major histocompatibility complex-mismatched liver allografts are often accepted spontaneously, 
in contrast to the rejection of other MHC-mismatched organs, such as the skin, heart and kidney.72 
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Apoptosis of inflammatory cells is prominent in spontaneously accepted liver allografts and is 
associated with a decline in the cytotoxic T lymphocyte activity of the graft-infiltrating cells.54 
The administration of IL-2 inhibits the apoptosis, increases the cytotoxic T lymphocyte activity of 
the graft-infiltrating cells and induces acute graft rejection. On the basis of these results, it has 
been suggested that T cell apoptosis in the liver may be responsible for spontaneous liver allograft 
acceptance.54 These findings are consistent with activation-induced apoptosis of alloreactive T 
cells in the liver, following interaction of the T cells with MHC-expressing hepatocytes that fail to 
provide the costimulation required to up-regulate the T cell levels of antiapoptotic Bcl-2-related 
proteins. The administration of IL-2 would increase the T cell levels of these anti-apoptotic pro-
teins and inhibit the T cell apoptosis, with resultant rejection of the allograft. The spontaneous 
rejection of other trans-planted organs, such as skin and heart, may be related to the smaller size 
and lower antigen load (from parenchymal cells and passenger leucocytes) of these organs.72 
Thus, in small allografts the alloreactive T cells may destroy the transplanted organ before the 
majority of these T cells have been deleted by activation-induced apoptosis. The spontaneous 
acceptance of multiple heart and kidney grafts in a single recipient that would rapidly reject these 
organs if they were transplanted singly73 is consistent with this concept. 
 
Possible role of T cell apoptosis in other organs  
 
Eye 
Apoptosis of inflammatory cells occurs in the anterior chamber of the eye infected by herpes 
simplex virus.74 This apoptosis is not observed in mutant mice lacking CD95 or CD95L 
expression, indicating that it is mediated through the CD95 pathway. Studies on radiation bone 
marrow chimeras have suggested that CD95L expression by resident cells of the eye inhibits 
inflammation and, by inference, is involved in the apoptotic process,74 although the role of CD95L 
expression by T cells was not examined. It was concluded that an interaction between CD95L-
expressing cells of the eye and CD95-expressing lymphocytes is responsible for this apoptosis and 
for the ‘immune privilege’ of the eye.74 According to this concept, activated T cells of all 
specificities would be deleted in the eye, which would have implications for the maintenance of T 
cell memory for all antigens, as discussed earlier for the proposal that activated T cells of any 
specificity are deleted in the CNS. An alternative possibility is that the main mechanism for T cell 
apoptosis in the eye is activation-induced apoptosis mediated by the inter-action of CD95 and 
CD95L on the same T cell, as has been proposed to occur in the CNS.46,47 This would result in the 
deletion of T cells encountering their specific antigen in the eye, but not in the deletion of other T 
cells. 
 
Testis 
One study has reported that testicular grafts expressing CD95L survive, whereas those not 
expressing CD95L are rejected when transplanted into allogeneic mice.75 Although apoptosis was 
not assessed, the authors concluded that an interaction between CD95L on testicular cells and 
CD95 on infiltrating T cells resulted in apoptosis of alloreactive T cells and graft acceptance and 
was responsible for the ‘immune privilege’ of the testis. Another study found that CD95L 
expression did not protect the testis from rejection.76 Further studies are needed to determine 
whether T cell apoptosis occurs in the testis, particularly in experimental autoimmune orchitis. 
 
Ovary 
Experimental autoimmune oophoritis is an autoimmune CD4+ T cell-mediated ovarian disease that 
is studied as a model of human premature ovarian failure. As in the case of acute EAE, mice 
immunized with a peptide of ZP3, a major glycoprotein in the zona pellucida, together with 
adjuvants, spontaneously recover from the disease and become resistant to disease reinduction.77 
Interestingly, although the previously inflamed endogenous ovaries are resistant to reinduction of 
disease, ovaries implanted after disease recovery are susceptible to oophoritis, indicating target 
organ resistance.77 The mechanism of target organ resistance has not been deter-mined, but one 
possible explanation is that there is increased activation-induced apoptosis of autoreactive T cells 
in the previously inflamed ovary as a result of increased availability of ovarian antigen and 
increased parenchymal class II MHC expression. It should be noted that the impact of activation-
induced apoptosis in the ovary on the peripheral lymphoid pool of ovary-reactive T cells may be 
considerably less than the impact of this process in the CNS on the peripheral lymphoid pool of 
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CNS-reactive T cells, because the smaller size of the ovary would result in it being a less effective 
‘sink’ for the elimination of ovary-reactive T cells. 
 
Salivary glands in primary Sjögren’s syndrome and synovia in rheumatoid arthritis 
Primary Sjögren’s syndrome is a chronic autoimmune disease characterized by T cell infiltration of 
the exocrine glands, including the salivary and lacrimal glands. One study found a low level of 
lymphocyte apoptosis in the periductal inflammatory foci of the salivary glands, compared with 
that in the interstitium.78 The authors suggested that impaired T cell apoptosis in the salivary gland 
may explain the chronic nature of the lesions. It has also been reported that there is a lack of T cell 
apoptosis in the inflammatory infiltrates in the synovia of patients with rheumatoid arthritis.79,80 
 
How does activation-induced apoptosis of antiviral T cells in the infected 
organ not prevent viral clearance? 
 
It would be expected that T cells directed against infectious agents would be deleted by activation-
induced apoptosis in infected organs. Apoptosis of inflammatory cells occurs in the virally 
infected CNS,81 eye74 and liver,82 although it has not been determined whether antiviral T cells are 
involved. How does activation-induced apoptosis of antiviral T cells in the infected organ not 
prevent viral clearance when the same apoptotic process in autoreactive T cells prevents auto-
immune disease? The most obvious explanation is the difference in antigen load. In the virally 
infected organ the total amount of viral antigen is likely to be much less than the total amount of 
individual major self-antigens. Thus, the antiviral T cells would be expected to clear the virus 
from the organ before a significant proportion of these T cells is eliminated by activation-induced 
apoptosis; once virus is cleared the antiviral T cells would continue to recirculate as memory cells. 
It is also possible that viral infection induces the expression of costimulatory molecules on 
normally non-professional parenchymal APC and that the costimulation up-regulates the levels of 
anti-apoptotic Bcl-2-related proteins in the antiviral T cells and thus inhibits T cell apoptosis. 
 
Conclusion 
In conclusion, there is increasing evidence that activation-induced apoptosis of previously activated 
autoreactive T cells in the target organ maintains immune tolerance and prevents autoimmune disease. 
Similarly, activation-induced apoptosis of alloreactive T cells in allografts can account for spontaneous 
allograft acceptance. 
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